发明授权
US09149544B2 Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
有权
钙磷硅酸盐纳米颗粒的生物缀合用于体内细胞的选择性靶向
- 专利标题: Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
- 专利标题(中): 钙磷硅酸盐纳米颗粒的生物缀合用于体内细胞的选择性靶向
-
申请号: US12941719申请日: 2010-11-08
-
公开(公告)号: US09149544B2公开(公告)日: 2015-10-06
- 发明人: Thomas T. Morgan , Brian M. Barth , James H. Adair , Rahul Sharma , Mark Kester , Sriram S. Shanmugavelandy , Jill P. Smith , Erhan I. Altinoglu , Gail L. Matters , James M. Kaiser , Christopher McGovern
- 申请人: Thomas T. Morgan , Brian M. Barth , James H. Adair , Rahul Sharma , Mark Kester , Sriram S. Shanmugavelandy , Jill P. Smith , Erhan I. Altinoglu , Gail L. Matters , James M. Kaiser , Christopher McGovern
- 申请人地址: US PA State College
- 专利权人: THE PENN STATE RESEARCH FOUNDATION
- 当前专利权人: THE PENN STATE RESEARCH FOUNDATION
- 当前专利权人地址: US PA State College
- 代理商 Laurence Weinberger
- 主分类号: A61K49/00
- IPC分类号: A61K49/00 ; A61K41/00 ; A61K47/48
摘要:
Non-aggregating resorbable calcium phosphosilicate nanoparticles (CPNPs) are bioconjugated to targeting molecules that are specific for particular cells. The CPNPs are stable particles at normal physiological pH. Chemotherapy and imaging agents may be integrally formed with the CPNPs so that they are compartmentalized within the CPNPs. In this manner, the agents are protected from interaction with the environment at normal physiological pH. However, once the CPNPs have been taken up, at intracellular pH, the CPNPs dissolve releasing the agent. Thus, chemotherapeutic or imaging agents are delivered to specific cells and permit the treatment and/or imaging of those cells. Use of the bioconjugated CPNPs both limits the amount of systemic exposure to the agent and delivers a higher concentration of the agent to the cell. The methods and principals of bioconjugating CPNPs are taught by examples of bioconjugation of targeting molecules for breast cancer, pancreatic cancer, and leukemia.
公开/授权文献
信息查询